Castle Biosciences price target raised to $45 from $40 at BTIG
BTIG raised the firm’s price target on Castle Biosciences (CSTL) to $45 from $40 and keeps a Buy rating on the shares. The company ...
Tactile Systems cut to Neutral at BTIG after Q3 revenue miss
Tactile Systems (TCMD) stock was downgraded by BTIG to neutral as its Q3 revenue misses expectations. Read more here.
bovnews12h
Ready Capital Corp (RC) Stock Settles at $6.71: What’s Contributing to This Price Point?
On Monday, Ready Capital Corp (RC) stock saw a decline, ending the day at $6.71 which represents a decrease of $-0.04 or -0.59% from the prior close of $6.75. The stock opened at $6.75 and touched a ...
Business Insider1d
BTIG Reaffirms Their Buy Rating on Revolve Group (RVLV)
BTIG analyst Janine Stichter maintained a Buy rating on Revolve Group (RVLV – Research Report) yesterday and set a price target of $30.00. The company’s shares closed yesterday at $25.27. According ...
Yahoo Finance5d
Wingstop lifted to Buy at BTIG, 'multiple levers remain'
Investing.com -- BTIG upgraded Wingstop (NASDAQ:WING) to Buy with a price target of $370 on Thursday, citing opportunities for long-term growth despite recent concerns around the company's fourth ...
bovnews13h
Synchrony Financial (SYF) Stock: Greater Than Its Current Valuation?
On Monday, Synchrony Financial (SYF) stock saw a decline, ending the day at $55.06 which represents a decrease of $-0.19 or -0.34% from the prior close of $55.25. The stock opened at $54.96 and ...
Stocks are poised for some downside volatility over the coming weeks, says BTIG's Krinsky
The S&P 500 was rising 0.3% on Tuesday afternoon, on pace for the 28th consecutive trading day where the large-cap benchmark index moved less than 1% in either direction, according to FactSet data.
Nasdaq6d
Wingstop upgraded to Buy from Neutral at BTIG
BTIG upgraded Wingstop (WING) to Buy from Neutral with a $370 price target The analyst cites the post-earnings selloff in the shares for the upgrade. The decline below $300 represents an ...
Yahoo Finance22d
Castle Biosciences price target raised to $40 from $35 at BTIG
BTIG raised the firm’s price target on Castle Biosciences (CSTL) to $40 from $35 and keeps a Buy rating on the shares. The firm is citing its call with a key opinion leader Dr. Raman Muthusamy ...
BTIG Remains a Hold on Douglas Emmett (DEI)
In a report released yesterday, Tom Catherwood from BTIG maintained a Hold rating on Douglas Emmett (DEI – Research Report). The ...
Nasdaq4d
Iqvia price target lowered to $260 from $290 at BTIG
BTIG lowered the firm’s price target on Iqvia (IQV) to $260 from $290 and keeps a Buy rating on the shares. The company’s total revenue, adjusted EBITDA, and adjusted EPS all exceeded ...